Chinese Demand For Immunity Supplements Drives Up Swisse's Sales
Executive Summary
Australian-heritage supplements brand Swisse capitalized on increased demand for immunity products during the COVID-19 pandemic to deliver sales growth of more than 25% in the first half of 2020.
You may also be interested in...
Blackmores To Cut Jobs As China Struggles Persist
With earnings slumping by over 60%, Australia's leading supplements player Blackmores is planning to cut 10% of its workforce as part of a restructuring effort to focus resources on turning around its ailing Chinese business.
Sweden Seeks To Tackle Opioid Overdose Deaths With Naloxone Rx-To-OTC Switch
Opioid antagonist naloxone will soon be available without prescription in Sweden following a successful Rx-to-OTC application from Norway's DNE Pharma.
Norway's Orkla Prioritizes Seeing Off Private-Label Consumer Health Challenge
Alongside addressing the threat posed by private-label, Orkla Health CEO Isabelle Ducellier will over the coming three years focus on building global brands and simplifying the value chain to improve efficiency and extract synergies.